DADC
ATYR

D.A. Davidson & Co’s aTyr Pharma ATYR Stock Holding History

D.A. Davidson & Co’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,650
Closed -$160K – 1600
2025
Q2 		$160K Sell
31,650
-8,550
-21% -$33.6K ﹤0.01% 1387
2025
Q1 		$121K Buy
40,200
+1,200
+3% +$4.38K ﹤0.01% 1362
2024
Q4 		$141K Buy
39,000
+10,000
+34% +$30.3K ﹤0.01% 1363
2024
Q3 		$51K Buy
29,000
+1,150
+4% +$2.09K ﹤0.01% 1358
2024
Q2 		$43.4K Buy
27,850
+1,500
+6% +$2.61K ﹤0.01% 1343
2024
Q1 		$51.4K Buy
26,350
+13,600
+107% +$23.7K ﹤0.01% 1360
2023
Q4 		$18K Sell
12,750
-10,000
-44% -$12.8K ﹤0.01% 1344
2023
Q3 		$35.9K Hold
22,750
– – ﹤0.01% 1302
2023
Q2 		$49.1K Buy
22,750
+10,750
+90% +$23.5K ﹤0.01% 1312
2023
Q1 		$25.2K Sell
12,000
-800
-6% -$1.75K ﹤0.01% 1324
2022
Q4 		$28K Buy
12,800
+1,000
+8% +$2.36K ﹤0.01% 1294
2022
Q3 		$35K Buy
11,800
+1,000
+9% +$3.35K ﹤0.01% 1260
2022
Q2 		$31K Buy
+10,800
New +$39K ﹤0.01% 1259
2017
Q2 		– Sell
-143
Closed -$7K – 2454
2017
Q1 		$7K Hold
143
– – ﹤0.01% 2118
2016
Q4 		$4K Buy
+143
New +$5.87K ﹤0.01% 2295
2016
Q3 		– Sell
-143
Closed -$5K – 2485
2016
Q2 		$5K Buy
+143
New +$6.65K ﹤0.01% 2133

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.A. Davidson & Co's ATYR Position: Q3 2025 in Review

D.A. Davidson & Co sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 31,650 shares — an estimated $160K sold.

D.A. Davidson & Co first reported a position in ATYR in Q2 2016 and held it in 16 quarters. The position peaked at $160K in Q2 2025. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.

  • D.A. Davidson & Co reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
  • D.A. Davidson & Co sold 31,650 aTyr Pharma shares in Q3 2025, an estimated $160K.
  • D.A. Davidson & Co first reported a position in aTyr Pharma in Q2 2016 and held it in 16 quarters.
  • D.A. Davidson & Co's aTyr Pharma position peaked at $160K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.

Based on D.A. Davidson & Co's 13F filing for Q3 2025, filed 22 Oct 2025.